Edition:
United States

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

2.71USD
3:39pm EST
Change (% chg)

$-0.25 (-8.45%)
Prev Close
$2.96
Open
$2.91
Day's High
$2.97
Day's Low
$2.71
Volume
294,314
Avg. Vol
231,873
52-wk High
$5.97
52-wk Low
$2.71

Latest Key Developments (Source: Significant Developments)

Akebia Therapeutics And Keryx Biopharmaceuticals Announce Chairperson For Combined Company
Thursday, 15 Nov 2018 05:15pm EST 

Nov 15 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS AND KERYX BIOPHARMACEUTICALS ANNOUNCE CHAIRPERSON FOR COMBINED COMPANY.AKEBIA THERAPEUTICS INC - UPON COMPLETION OF MERGER, BOARD OF DIRECTORS WILL CONSIST OF TEN MEMBERS WITH ADAMS AS CHAIRPERSON..AKEBIA THERAPEUTICS INC - CURRENT AKEBIA BOARD MEMBER MAXINE GOWEN WILL CONTINUE TO SERVE AS A MEMBER OF BOARD.AKEBIA THERAPEUTICS - CO, KERYX SAYS ADRIAN ADAMS WILL SERVE AS CHAIRPERSON OF AKEBIA BOARD OF DIRECTORS, EFFECTIVE UPON PROPOSED MERGER COMPLETION.  Full Article

Akebia Therapeutics Sends Letter To Shareholders
Tuesday, 13 Nov 2018 04:05pm EST 

Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS SENDS LETTER TO SHAREHOLDERS.AKEBIA THERAPEUTICS - AKEBIA BOARD UNANIMOUSLY RECOMMENDS THAT AKEBIA SHAREHOLDERS VOTE "FOR" PROPOSALS RELATING TO PROPOSED MERGER WITH KERYX.  Full Article

Keryx Biopharmaceuticals Q4 Loss Per Share $0.26
Wednesday, 7 Feb 2018 07:00am EST 

Feb 7 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.26.Q4 REVENUE $18.7 MILLION VERSUS $9.5 MILLION.CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 TOTALED ABOUT $93.5 MILLION.  Full Article

Keryx Biopharma Says Norwich Pharmaceuticals Agreed To Terminate Manufacturing Services Agreement
Wednesday, 27 Dec 2017 04:37pm EST 

Dec 27 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS- ON DEC 20,CO,NORWICH PHARMACEUTICALS AGREED TO TERMINATE MANUFACTURING SERVICES AGREEMENT BETWEEN CO,NPI,DATED JAN 17, 2014‍​.KERYX BIOPHARMACEUTICALS SAYS ‍TERMINATION OF AGREEMENT EFFECTIVE AS OF DEC 31, 2017​ - SEC FILING.  Full Article

U.S. FDA approves Auryxia tablets as treatment for people with iron deficiency anemia and chronic kidney disease
Tuesday, 7 Nov 2017 07:01am EST 

Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc :U.S. FDA approves Auryxia® (ferric citrate) tablets as a treatment for people with iron deficiency anemia and chronic kidney disease, not on dialysis.  Full Article

Keryx Biopharmaceuticals Q3 loss per share $0.20
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc :Keryx Biopharmaceuticals announces third quarter 2017 financial results.Q3 loss per share $0.20.Q3 revenue $15 million versus I/B/E/S view $17.9 million.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Keryx Biopharmaceuticals Inc- ‍cash and cash equivalents as of Sept 30, 2017 totaled $114.0 million compared to $111.8 million as of Dec 31, 2016​.  Full Article

KERYX BIOPHARMACEUTICALS SAYS MICHAEL ROGERS APPOINTED CHAIRMAN OF BOARD
Wednesday, 13 Sep 2017 04:10pm EDT 

Sept 13 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS.SAYS MICHAEL ROGERS APPOINTED CHAIRMAN OF THE BOARD.KERYX BIOPHARMACEUTICALS INC- MICHAEL ROGERS SUCCEEDS JOHN BUTLER WHO HAS RESIGNED FROM KERYX'S BOARD.  Full Article

Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​
Friday, 1 Sep 2017 05:02pm EDT 

Sept 1 (Reuters) - Keryx Biopharmaceuticals Inc :Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​.Keryx Biopharma - new ‍product agreement is in addition to two agreements entered under master agreement for Patheon's manufacture of Auryxia tablets​.Keryx Biopharmaceuticals Inc - ‍product agreement has an initial term ending December 31, 2024​.Keryx Biopharmaceuticals Inc - ‍ also product agreement will automatically renew after initial term for successive terms of two years each​.  Full Article

Keryx Biopharmaceuticals Q2 loss per share $0.77
Thursday, 27 Jul 2017 07:01am EDT 

July 27 (Reuters) - Keryx Biopharmaceuticals Inc ::Keryx Biopharmaceuticals announces second quarter 2017 financial results and increased 2017 u.s. Product sales guidance.Q2 loss per share $0.77.Q2 revenue $15.1 million versus I/B/E/S view $14.5 million.Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Keryx Biopharmaceuticals Inc - "Q2 gives us confidence to raise Auryxia's 2017 net product sales guidance to $62 to $66 million".Keryx Biopharmaceuticals Inc -sees full year 2017 net U.S. Auryxia product sales to $62 to $66 million from $56 to $60 million.Keryx Biopharmaceuticals Inc - cash and cash equivalents as of June 30, 2017 totaled $140.5 million compared to $111.8 million as of December 31, 2016..  Full Article

Keryx Biopharmaceuticals Q1 loss per share $0.21
Thursday, 4 May 2017 07:02am EDT 

May 4 (Reuters) - Keryx Biopharmaceuticals Inc ::Keryx Biopharmaceuticals announces first quarter 2017 financial results.Q1 loss per share $0.21.Q1 revenue $11.8 million versus I/B/E/S view $10.3 million.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Sees for full year 2017 net u.s. Auryxia product sales of $56 to $60 million.Keryx biopharmaceuticals - q1 2017 net u.s. Auryxia product sales of $10.5 million versus $5.6 million in q1 of 2016.  Full Article